Nilanjan Ghosh, MD, PhD
PET-adapted therapy has been incorporated for the last 5 to 7 years in Hodgkin lymphoma, says Nilanjan Ghosh, MD, PhD, a physician at Levine Cancer Institute.
on Hematologic Malignancies, Ghosh discussed the advances and ongoing research in frontline treatment of patients with Hodgkin lymphoma.
OncLive: Please provide an overview of your presentation.
: I spoke about the frontline treatment of early-stage and advanced-stage Hodgkin lymphoma. I presented some of the data about PET-adapted treatment in newly diagnosed Hodgkin lymphoma, as well as the introduction of brentuximab vedotin (Adcetris) with adriamycin, vinblastine, and dacarbazine (AVD). Brentuximab vedotin with AVD is a non-PET–adapted treatment and has been recently FDA approved in the frontline treatment of patients with stage III and IV Hodgkin lymphoma.
... to read the full story